4//SEC Filing
Kelley Lynne E 4
Accession 0000899243-18-026060
CIK 0001372299other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 5:03 PM ET
Size
8.5 KB
Accession
0000899243-18-026060
Insider Transaction Report
Form 4
HISTOGENICS CORPHSGX
Kelley Lynne E
Chief Medical Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−200,000→ 0 totalExercise: $2.21Exp: 2028-07-30→ Common Stock (200,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+200,000→ 200,000 totalExercise: $0.57Exp: 2028-07-30→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" (any stock option awarded by the Issuer under it 2012 Equity Incentive Plan or 2013 Equity Incentive Plan with an exercise price greater than $ 0.75628 per share held by current service providers other than the non-employee members of the Issuer's board of directors) has been amended to reduce such exercise price to $0.568, which was the closing price of a share of the Issuer's common stock reported on The Nasdaq Capital Market on October 1, 2018. There have been no other changes to the terms of the Relevant Options.
- [F2]The stock option was originally granted to the Reporting Person on July 31, 2018. This option vests over four (4) years of service following July 31, 2018, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and in thirty-six (36) equal monthly installments thereafter.
Documents
Issuer
HISTOGENICS CORP
CIK 0001372299
Entity typeother
Related Parties
1- filerCIK 0001667584
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 5:03 PM ET
- Size
- 8.5 KB